SUN Caihong, KONG Dongsheng, LIU Ruoyu, LIU Fang, ZHAO Kai, ZHAO Junyan. Comparison of clinical features and prognosis of oligodendroglioma versus astrocytoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2022, 43(5): 536-539. DOI: 10.3969/j.issn.2095-5227.2022.05.008
Citation: SUN Caihong, KONG Dongsheng, LIU Ruoyu, LIU Fang, ZHAO Kai, ZHAO Junyan. Comparison of clinical features and prognosis of oligodendroglioma versus astrocytoma[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2022, 43(5): 536-539. DOI: 10.3969/j.issn.2095-5227.2022.05.008

Comparison of clinical features and prognosis of oligodendroglioma versus astrocytoma

More Information
  • Corresponding author:

    ZHAO Kai. Email: jsaondna124@163.com

    ZHAO Junyan. Email: zhaojunyan_301@163.com

  • Received Date: October 06, 2021
  • Available Online: April 20, 2022
  •   Background  Glioma is the most common primary central system tumor in human. Among them, WHO grade 2 adult-type diffuse gliomas include oligodendroglioma and astrocytoma. The two types of tumors have different origins. Although surgery, radiotherapy and adjuvant temozolomide chemotherapy are currently used, there are differences in biological behavior, molecular pathology, sensitivity to radiotherapy and chemotherapy, and prognosis of the two groups.
      Objective  To explore the clinical features, molecular pathology results, prognosis, and adverse effects of temozolomide treatment of oligodendroglioma and astrocytoma, so as to provide a theoretical reference for optimizing the long-term temozolomide regimen for patients with low-grade glioma.
      Methods  Clinical data about 60 patients with low-grade (WHO class Ⅱ) glioma who underwent neurosurgical treatment and regular radiotherapy and chemotherapy (temozolomide for at least 3 cycles) in the First Medical Center of Chinese PLA General Hospital from January 2016 to June 2021 were retrospectively analyzed. Among them, 37 cases were simple oligodendroglioma and 23 cases were astrocytoma. The tumor invasion site, molecular pathological results, incidence of temozolomide adverse reactions, progression-free survival (PFS) and overall survival (OS) were compared between the two groups.
      Results  Compared with astrocytoma, oligodendroglioma had a higher frequency of MGMT promoter methylation (81.08% vs 56.52%, P=0.04), and longer PFS (P=0.034) and OS (P=0.028). However, oligodendroglioma and astrocytoma had no statistical difference in tumor invasion sites and incidence of TMZ side effects.
      Conclusion  Oligodendroglioma has better biological characteristics than astrocytoma. Patients with oligodendroglioma have longer progression-free survival and overall survival after the same total resection of tumor and postoperative radiotherapy and chemotherapy, but there is no difference in incidence of TMZ side effects.
  • [1]
    李朝晖,郭志钢,李庆伟. 弥漫性较低级别胶质瘤的整合性分子病理分型研究进展[J]. 中国肿瘤临床,2016,43(12): 541-544. doi: 10.3969/j.issn.1000-8179.2016.12.340
    [2]
    Louis DN,Arie P,Pieter W,et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro-oncology,2021,23(8): 1231-1251. doi: 10.1093/neuonc/noab106
    [3]
    Weller M,Pfister SM,Wick W,et al. Molecular neuro-oncology in clinical practice: a new horizon[J]. Lancet Oncol,2013,14(9): e370-e379. doi: 10.1016/S1470-2045(13)70168-2
    [4]
    徐维林,王强,张宏伟,等. 长周期替莫唑胺治疗高级别胶质瘤生存期观察[J]. 解放军医学院学报,2016,37(7): 725-727. doi: 10.3969/j.issn.2095-5227.2016.07.015
    [5]
    Stupp R,Mason WP,van den Bent MJ,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med,2005,352(10): 987-996. doi: 10.1056/NEJMoa043330
    [6]
    Stupp R,Taillibert S,Kanner A,et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma[J]. JAMA,2017,318(23): 2306. doi: 10.1001/jama.2017.18718
    [7]
    周苏娜,张琰君,何东杰,等. 低级别胶质瘤36例患者术后放疗的预后分析[J]. 山西医科大学学报,2016,47(9): 847-850.
    [8]
    Bell EH,Zhang PX,Fisher BJ,et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial[J]. JAMA Oncol,2018,4(10): 1405-1409. doi: 10.1001/jamaoncol.2018.1977
    [9]
    Lakomý R,Kazda T,Poprach A,et al. The role of chemotherapy in the treatment of low-grade gliomas[J]. Klin Onkol,2017,30(5): 343-348.
    [10]
    朱巍,崔萌,马晓东. 岛叶低级别胶质瘤的生物学特性及预后评估[J]. 解放军医学院学报,2018,39(1): 5-8. doi: 10.3969/j.issn.2095-5227.2018.01.002
    [11]
    Eckel-Passow JE,Lachance DH,Molinaro AM,et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors[J]. N Engl J Med,2015,372(26): 2499-2508. doi: 10.1056/NEJMoa1407279
    [12]
    Tanriverdi T,Kemerdere R,Baran O,et al. Long-term surgical and seizure outcomes of frontal low-grade gliomas[J]. Int J Surg,2016,33(Pt A): 60-64.
    [13]
    陈海南,莫立根,邓腾. MGMT基因对脑胶质瘤患者启动子甲基化变化的价值研究[J]. 中国实用神经疾病杂志,2016,19(6): 61-62. doi: 10.3969/j.issn.1673-5110.2016.06.040
    [14]
    郭超. 脊髓胶质瘤MGMT基因启动子甲基化及蛋白表达对替莫唑胺敏感性的临床观察[D]. 唐山: 华北理工大学, 2016.
    [15]
    Wijnenga MMJ,Mattni T,French PJ,et al. Does early resection of presumed low-grade glioma improve survival?A clinical perspective[J]. J Neurooncol,2017,133(1): 137-146. doi: 10.1007/s11060-017-2418-8
    [16]
    Baumert BG,Hegi ME,van den Bent MJ,et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study[J]. Lancet Oncol,2016,17(11): 1521-1532. doi: 10.1016/S1470-2045(16)30313-8
    [17]
    Kashi AS,Rakhsha A,Houshyari M. Overall survival in adult patients with low-grade, supratentorial glioma: ten years' follow up at a single institution[J]. Electron Physician,2015,7(3): 1114-1120.
  • Cited by

    Periodical cited type(1)

    1. 吴小延,王苏杰,王芳,杜紫明,邓玲. IDH突变和1p/19q共缺失型少突胶质细胞瘤临床病理特征和预后分析. 肿瘤防治研究. 2024(03): 178-184 .

    Other cited types(1)

Catalog

    Article Metrics

    Article views (361) PDF downloads (20) Cited by(2)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return